Novo Nordisk surges as Wegovy secures FDA approval for MASH, marking a breakthrough in liver care and expanding its blockbuster reach.

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, at a cash price of $499 per month.

Tools like Claimable and Fight Health Insurance use AI to guide people through the insurance appeals process and generate ...

Longer-term studies will be needed to track whether per-patient costs might drop over time with continued use of the meds.

GoodRx (GDRX) is joining in on the GLP-1 action with an announcement on Monday that it will begin selling both of Novo Nordisk's (NVO) GLP-1 drugs, Ozempic for diabetes and Wegovy for weight loss, at ...

Novo Nordisk NVO faced a significant setback in July after sharply reducing its 2025 outlook for both sales and operating ...

Last year, GLP-1s dominated many employer conversations as demand surged and pressure mounted from employees clamoring for ...

See the latest CVS stock price NYSE: CVS stock rating, related news, valuation, dividends and more to help you make your investing decisions.

Shares in Eli Lilly have weakened after pharmacy benefit manager CVS Health said it would no longer cover its weight-loss therapy Zepbound.

What does CVS’s acquisition mean for the future of healthcare? Just as two-day delivery and food delivery services aren’t going anywhere, home healthcare is here to stay.

Ozempic can be used off-label for prediabetes, but that use may not be covered. Learn more about Medicare prevention, how coverage of Ozempic compares with Wegovy, and more.